Quantcast

Latest Genmab Stories

2010-04-29 13:54:00

PHILADELPHIA, April 29 /PRNewswire/ -- TenX Biopharma, Inc., announced today it has signed a Clinical Trial Agreement with the National Cancer Institute (NCI) to conduct an investigator sponsored Phase II clinical trial. For this study, the NCI's Surgery Branch Chief, Dr. Steven A. Rosenberg, will lead a Phase II clinical trial investigating the combination of TenX Biopharma's zanolimumab, an investigational anti-CD4 therapeutic antibody, with aldesleukin (IL-2) for the treatment of...

2010-02-04 13:16:00

PHILADELPHIA, Feb. 4 /PRNewswire/ -- TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S (OMX: GEN). Under the terms of the agreement, Genmab will receive an up-front license fee of USD 4.5 million and will be entitled to milestones and royalties on sales of zanolimumab. TenX will be responsible for all future costs of developing,...

2010-01-15 10:06:00

SCOTTSDALE, Ariz., Jan. 15 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat hematologic malignancies. These reports are based on primary interviews conducted with hematologists from North America immediately following the American Society of Hematology (ASH) annual meeting. This report, entitled "Thought...

2009-11-06 09:37:00

SCOTTSDALE, Ariz., Nov. 6 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus. "Of all the diseases rheumatologists treat, lupus still has the highest unmet need," according to MedPredict president Jeffrey Berk. "While many more people...

2009-11-05 11:09:00

NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight http://www.reportlinker.com/p0158341/Monoclonal-Antibody-Therapies-2007-Competitive-Landscape-and-Pipeline-Insight.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24...

2009-10-26 14:14:00

NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment http://www.reportlinker.com/p0156557/Reportlinker-Adds-Monoclonal-Antibodies-Pipeline-Analysis-and-Competitive-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire In the nearly 35 years since the first process for creating mAbs was introduced, they...

2009-10-26 13:15:00

NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications http://www.reportlinker.com/p0155768/Reportlinker-Adds-Immunotherapies-and-Vaccines-for-Nontraditional-Indications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Executive Summary The earliest immunotherapies were vaccines that stimulate the immune system's...

2009-05-29 12:12:00

ORLANDO, Fla., May 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: GEN] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to three that the ARZERRA(TM) (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab. Ofatumumab is an investigational treatment. "The...

d0280504311ba0aceafddc5c9d527b7e1
2009-05-28 06:30:00

U.S. drug regulators are carefully scrutinizing a new leukemia drug from pharmaceutical giant GlaxoSmithKline PLC and Genmab to determine whether the medication offers patients enough benefit to sanction its approval. Officials from the U.S. Food and Drug Administration stated that the exact degree of anti-cancer activity provided by the drug has proven "difficult to quantify" in patients with chronic lymphocytic leukemia (CLL), one of the more common varieties of adult blood cancer. "The...

2009-04-30 05:00:00

PRINCETON, N.J., April 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter ended March 31, 2009. Medarex's net loss for the quarter ended March 31, 2009 was $48.6 million, or ($0.38) per share. For the same period in 2008, Medarex's net income of $103.3 million, or $0.81 per share, included a gain of $151.8 million, or $1.19 per share, from the sale of 2.5 million shares of Genmab A/S stock in February 2008. Medarex's net loss for...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.